Shares of Basilea Pharmaceutica shot up as speculation about a possible takeover attempts heats up. Basilea recently won a $130 million arbitration award from J&J, which was held responsible for botching clinical trial work on ceftobiprole. The anti-infective was shot down by regulators in Europe and the U.S. after they determined that the data presented was unreliable. Now the biotech's low market value, pipeline of new anti-infectives and cash in the bank has made it an attractive takeover target, according to some analysts. Story